VYKAT XR (diazoxide choline)

AbsorptionFollowing oral administration, diazoxide choline is hydrolyzed to diazoxide prior to absorption. Peak diazoxide concentrations occur after 16 hours. VYKAT XR is expected to reach steady state after 7 days. Effect of Food Following administration of 150 mg diazoxide choline to healthy subjects, the C max increased by 39% and AUC inf was unchanged with a high-fat meal, compared to fasted conditions. The median T max was 12 hours in the fasted state, and 8 hours in the fed state. Distrib...

The efficacy of VYKAT XR for the treatment of hyperphagia in adults and pediatric patients ages 4 years and older with PWS was established in a 16-week, double-blind, placebo-controlled, randomized withdrawal study period (Study 2-RWP; NCT03714373) that followed an open-label study period of VYKAT XR. During Study 2-RWP, 77 patients with hyperphagia and PWS were randomized in a 1:1 ratio to continue their current oral dosage using a weight-based dosage regimen of VYKAT XR or placebo [see Dosage and Adminstration (2.2) ] . Prior to participating in Study 2-RWP, patients received double-blind an...

The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling: Hyperglycemia [see Warnings and Precautions (5.1) ] Risk of Fluid Overload [see Warnings and Precautions (5.2) ] Adverse Reactions from Clinical Studies of VYKAT XR in Patients with PWS Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical tri...

VYKAT XR is contraindicated in patients with known hypersensitivity to diazoxide, other components of VYKAT XR, or to thiazides. Erythema multiforme has been reported with VYKAT XR [see Adverse Reactions (6) ] . Known hypersensitivity to diazoxide, other components of VYKAT XR, or to thiazides. ( 4 )

Hyperglycemia : Hyperglycemia, including diabetic ketoacidosis, has been reported. During treatment, monitor fasting glucose and HbA1c. Monitor fasting glucose more frequently during first few weeks of treatment in patients with risk factors for hyperglycemia. ( 2.3 , 5.1 ) Risk of Fluid Overload : Edema, including severe reactions associated with fluid overload, has been reported. Monitor for signs or symptoms of edema or fluid overload. ( 2.3 , 5.2 ) 5.1 Hyperglycemia VYKAT XR increases blood ...

7 DRUG INTERACTIONS Table 4 displays clinically significant drug interactions with VYKAT XR.

Table 4Clinically Significant Drug Interactions with VYKAT XR Strong CYP1A2 Inhibitors See www.fda.gov/CYPandTransporterInteractingDrugs for examples of strong CYP1A2 and CYP3A4 inhibitors, sensitive CYP1A2 substrates, and dual strong CYP3A4 / moderate 1A2 inducers. Prevention or Management Reduce the do...